Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Achieve Life Sciences Inc ACHV

Healthcare Biotechnology
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of... see more

Recent & Breaking News (NDAQ:ACHV)

Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

GlobeNewswire July 11, 2023

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

GlobeNewswire June 6, 2023

Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

GlobeNewswire May 25, 2023

Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

GlobeNewswire May 23, 2023

Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank

GlobeNewswire May 17, 2023

Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update

GlobeNewswire May 9, 2023

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

GlobeNewswire April 26, 2023

Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline

GlobeNewswire April 20, 2023

Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference

GlobeNewswire April 14, 2023

Achieve Life Sciences Announces Refresh to Board of Directors

GlobeNewswire March 30, 2023

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

GlobeNewswire March 29, 2023

Achieve Life Sciences Announces Granting of New Hire Inducement Award

GlobeNewswire March 17, 2023

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

GlobeNewswire March 16, 2023

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

GlobeNewswire March 8, 2023

Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

GlobeNewswire March 3, 2023

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023

GlobeNewswire March 2, 2023

Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

GlobeNewswire February 7, 2023

Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference

GlobeNewswire February 2, 2023

Achieve Life Sciences Announces Granting of New Hire Inducement Award

GlobeNewswire January 27, 2023

Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

GlobeNewswire January 9, 2023